To test this possibility, we first evaluated the expression of p53 in response to titrated doses of Olaparib, and found that p53 is upregulated in both HCT116 p53+/+ colorectal cancer cells and Cal51 breast cancer cells in a dose-dependent fashion (Figures 1A, C). This evidence concerns the gene TP53 and breast cancer.